Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.89 USD | -14.15% | -13.58% | -34.30% |
04-26 | Morgan Stanley Trims Accolade's Price Target to $12 From $13, Maintains Equal Weight Rating | MT |
04-25 | Transcript : Accolade, Inc., Q4 2024 Earnings Call, Apr 25, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 66% by 2027.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.92 for the current period. Therefore, the company is undervalued.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-34.30% | 618M | C- | ||
-14.92% | 84.68B | B- | ||
+13.30% | 81.12B | C+ | ||
+11.62% | 29.4B | C+ | ||
-12.71% | 16.73B | B | ||
-3.06% | 16.36B | A- | ||
-2.63% | 14.92B | A- | ||
-31.75% | 11.77B | - | - | |
-1.42% | 11.72B | A- | ||
+27.44% | 11.71B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ACCD Stock
- Ratings Accolade, Inc.